- Conditions
- Hypertension, COVID
- Interventions
- ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 215
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Idiopathic Dilated Cardiomyopathy
- Interventions
- Carvedilol, Metoprolol succinate, Metoprolol succinate + doxazosin
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Salt Lake City, Utah
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- End Stage Renal Disease on Dialysis
- Interventions
- Dry weight target adjustment, Anti-hypertensive medications
- Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- San Francisco, California • Seattle, Washington
- Conditions
- Acute Decompensated Heart Failure, Heart Failure
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Hypertension
- Interventions
- Nebivolol
- Drug
- Lead sponsor
- Mylan Bertek Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Heart Failure
- Interventions
- GUIDED-HF, Standard of Care
- Behavioral
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 15
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 11 more
- Conditions
- Heart Failure, Heart Failure, Systolic
- Interventions
- Pharmacist/Cardiologist Virtual Team Digital Consultation
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 585 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Radiation Induced Fibrosis
- Interventions
- Losartan 25 milligram capsule, Placebo
- Drug
- Lead sponsor
- Shaw Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Edwards, Colorado
- Conditions
- Alzheimer's Disease
- Interventions
- Carvedilol, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Up to 100 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Decompensated Liver Cirrhosis, Cirrhosis, Decompensated Cirrhosis of Liver, Decompensated Cirrhosis and Ascites
- Interventions
- Atorvastatin 20 mg, Placebo
- Drug
- Lead sponsor
- CAMC Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, West Virginia
- Conditions
- Coronary Atherosclerosis
- Interventions
- Cardiac MRI, Contrast, Beta blocker
- Device · Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Carvedilol, Laboratory Biomarker Analysis, Patient Observation
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 577
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Propranolol Oral Tablet, Placebo Oral Tablet
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Esophageal Adenocarcinoma
- Interventions
- Carboplatin, 3 Dimensional Conformal Radiation Therapy, Propranolol, Intensity Modulated Radiation Therapy, Paclitaxel
- Drug · Radiation
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Heart Diseases
- Interventions
- Metoprolol Tartrate, Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • St Louis, Missouri
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- beta blocker discontinuation
- Other
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Hypertension, Female Sexual Dysfunction
- Interventions
- nebivolol and metoprolol succinate, metoprolol succinate and nebivolol
- Drug
- Lead sponsor
- East Coast Institute for Research
- Network
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Atrial Fibrillation, Atrial Flutter
- Interventions
- Oral, Intravenous drug
- Drug
- Lead sponsor
- Corewell Health South
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Saint Joseph, Michigan
- Conditions
- High Blood Pressure
- Interventions
- Nebivolol, Metoprolol XL
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Insulin Sensitivity, Obesity
- Interventions
- Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption
- Other
- Lead sponsor
- Rutgers University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Acute Coronary Syndrome
- Interventions
- Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 3,503 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 91
- States / cities
- Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
- Interventions
- Beta blockers
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure
- Interventions
- Omecamtiv Mecarbil, Placebo, Standard of Care
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 8,256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 310
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 249 more